Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease

URL

https://www.atsjournals.org/doi/10.1164/rccm.202111-2606OC

Authors

Takafumi Kato, Takanori Asakura, Caitlin E. Edwards, Hong Dang, Yu Mikami, Kenichi Okuda, Gang Chen, Ling Sun, Rodney C. Gilmore, Padraig Hawkins, Gabriela De la Cruz, Michelle R. Cooley, Alexis B. Bailey, Stephen M. Hewitt, Daniel S. Chertow, Alain C. Borczuk, Steven Salvatore, Fernando J. Martinez, Leigh B. Thorne, Frederic B. Askin, Camille Ehre, Scott H. Randell, Wanda K. O’Neal, Ralph S. Baric, Richard C. Boucher, and NIH COVID-19 Autopsy Consortium

Published Date

July 11, 2022

Publication

American Journal of Respiratory and Critical Care Medicine

Organization

Marsico Lung Institute

Key Excerpts

“Conclusions: SARS-CoV-2 infection is associated with a high prevalence of distal airspace mucus accumulation and increased MUC5B expression in COVID-19 autopsy lungs. HBE culture studies identified roles for EGFR and IL-1R signaling in mucin gene regulation after SARS-CoV-2 infection. These data suggest that time-sensitive mucolytic agents, specific pathway inhibitors, or corticosteroid administration may be therapeutic for COVID-19 lung disease.”

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0.

Medium

document

Topics

COVID-19,medical treatments